Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NQO2 | P16083 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686650 | 1.00 | MTNR1A (0.61) | MTNR1AMTNR1BTAAR1MEN1LMNA | |
| SCHEMBL2543023 | 0.90 | MTNR1A (0.52) | MTNR1AMTNR1BTAAR1 | |
| SCHEMBL3638162 | 0.84 | TAAR1 (0.56) | MTNR1AMTNR1BTAAR1LMNAKMT2A | |
| SCHEMBL12851863 | 0.83 | TAAR1 (0.56) | MTNR1AMTNR1BTAAR1KMT2ANQO2 | |
| SCHEMBL30878491 | 0.83 | TAAR1 (0.56) | MTNR1AMTNR1BTAAR1CYP1A2CYP2C19 | |
| SCHEMBL33530786 | 0.83 | TAAR1 (0.56) | MTNR1AMTNR1BTAAR1 | |
| SCHEMBL5988458 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL102342 | 0.81 | RIPK1 (0.61) | MTNR1AMEN1LMNAPKMKMT2A | |
| SCHEMBL8229644 | 0.81 | MTNR1A (0.65) | MTNR1AMTNR1BMEN1LMNACYP1A2 | |
| SCHEMBL1039416 | 0.80 | MTNR1A (0.63) | MTNR1AMTNR1BMEN1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3993795-B1 | A SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVE AS A D1 POSITIVE ALLOSTERIC MODULATOR | UCB Biopharma SRL (BE) | 2026-04-22 | — | — | EP | disclosed |
| US-12358890-B2 | Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator | UCB Biopharma SRL (BE) | 2025-07-15 | — | — | US | disclosed |
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | UCB Biopharma SRL (BE) | 2024-02-08 | — | — | US | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219923-A1 | KINASE INHIBITORS | VIDYA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| CN-115867346-A | Kinase inhibitors | GB005股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20220251064-A1 | A Substituted Tetrahydroisoquinoline Derivative as a D1 Positive Allosteric Modulator | UCB Biopharma SRL (BE) | 2022-08-11 | — | — | US | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022117678-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2022-06-09 | — | — | WO | disclosed |
| EP-2090576-A1 | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators | Merz Pharma GmbH & Co.KGaA (DE) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009095253-A1 | 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2009-08-06 | — | — | WO | disclosed |
| CN-101501036-A | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO KGAA (DE) | 2009-08-05 | — | — | CN | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358890-B2 | Substituted tetrahydroisoquinoline derivative as a D1 positive allosteric modulator | OPRD1, ADRA1D, GPR52 | MTNR1A 14/4885MTNR1B 43/4885TAAR1 201/4885 |
| US-20220251064-A1 | A Substituted Tetrahydroisoquinoline Derivative as a D1 Positive Allosteric Modulator | OPRD1, ADRA1D, GPR52 | MTNR1A 15/4885MTNR1B 29/4885TAAR1 201/4885 |
| US-20230219923-A1 | KINASE INHIBITORS | BTK, ABL1, LYN | MTNR1A 2813/4885MTNR1B 2932/4885TAAR1 3038/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | MTNR1A 462/4885MTNR1B 345/4885TAAR1 571/4885 |
| US-20240043400-A1 | Octahydroisoquinolinyl Derivatives | OPRD1, OPRK1, OPRL1 | MTNR1A 53/4885MTNR1B 70/4885TAAR1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.